on the research side, this would tend to reduce prices, right? clinical trials usually aren't charging (per [1]). this 2017 article[2] claims that the US pharm

on the research side, this would tend to reduce prices, right? clinical trials usually aren't charging (per [1]). this 2017 article[2] claims that the US pharma $ premium is more than R&D spending for 13 of 15 top pharma cos. (Note: this isn't even talking about profit, it's talking about the excess profit from higher US prices). Maybe you can make an argument that R&D is lockstep to margins, and would shrink if margins went down? 1. https://www.hhs.gov/ohrp/sachrp-committee/recommendations/november-20-2019-attachment-a/index.html https://www.hhs.gov/ohrp/sachrp-committee/recommendations/no... 2. https://www.healthaffairs.org/do/10.1377/forefront.20170307.059036/ https://www.healthaffairs.org/do/10.1377/forefront.20170307....